References
- Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). Cochrane Library, Oxford. Issue 2, 2003, and ALS and Other Motor Neuron Disords 2003; 191–206.
- Griggs RC, Moxley RG III, Mendell JR et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Arch Neurol 1991; 48: 383.
- Fenichel GM, Florence JM, Pestronk A et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874.
- Anonymous. Adding a humanized antibody to vascular endo- thelial growth factor (bevacizumib, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003; 9: 65–88.
- Lai EC, Felice KJ, Festoff BW et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621–1630.
- Miller RG, Moore DH, Gelinas DF et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
- Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003; 61: 1503–1507.
- Moore DH, Miller RG, WALS Study Groupthe ALS Care Study Group. ALSFRS as a measure of disease progression and a predictor of survival. Amyotroph Lateral Scler and Other Motor Neuron Disords 2003; 4: 42.
- Florence HM, Moore DH, Mendoza M et al. Validation of Telephonic Administration of the ALSFRSR. (American Academy of Neurology 56th Annual Meeting) Neurology 2004; 7(suppl 5): A134.